TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 10/19/23

2023-10-19 18:23:58 ET Summary Hutchmed's 2023 interim financial report shows progress towards profitability, with revenue from product sales and R&D services increasing. The company has a strong balance sheet with $856 million in cash and a low level of bank borrowings. T...

Approval Based on Updated Positive Overall Survival Results from the Phase 3 ECHELON-1 Study for Stage III & IV Hodgkin Lymphoma First Significant Improvement in Overall Survival in Two Decades in Stage III & IV Hodgkin Lymphoma Approval Expands on Six Current Indi...

2023-10-18 14:00:05 ET More on Takeda Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade) Takeda Pharmaceutical Company Limited (TAK) Q1 2023 Earnings Call Transcript Takeda to voluntarily pull lung cancer drug Exkivity from U.S. market Ta...

Takeda ( TSE:4502/NYSE:TAK ) today announced that, on October 17, 2023 (IST), it agreed with the Irish Revenue Commissioners (“Irish Revenue”) to settle a tax assessment related to the treatment of an acquisition break fee received by Shire plc (“Shire”) in October...

Takeda (TSE:4502/NYSE: TAK) today announced that the Phase 3 ADMIRE-CD II study, assessing the efficacy and safety of Alofisel ® (darvadstrocel) for the treatment of complex Crohn’s Perianal Fistulas (CPF), did not meet its primary endpoint of combined remission at 24 weeks, based...

Takeda Receives Corporate Leader Award from the Daily Bread Food Bank Canada NewsWire TORONTO , Oct. 5, 2023 /CNW/ - Takeda Canada Inc. ("Takeda"), a leading biopharmaceutical company, is pleased to announce it has received the Corporate Leader Award by the ...

2023-10-05 12:43:14 ET Summary Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug candidate. The company ended the second quarter w...

2023-10-04 12:32:07 ET More on Harmony Biosciences Harmony Biosciences: A Balancing Act As Investors Lose Some Sleep Harmony Biosciences Holdings, Inc. 2023 Q2 - Results - Earnings Call Presentation Harmony Biosciences Holdings, Inc. (HRMY) Q2 2023 Earnings Call Tran...

2023-10-04 07:14:23 ET Summary Ovid Therapeutics' OV329 shows promise in early Phase 1 data for treating pharmacoresistant epilepsy, boasting superior pharmacokinetics and safety profiles. Financials are strong with a robust current ratio of 10.1 and 24-month cash runway, but cash...

Experts Reviewed Data from QDENGA’s Clinical Program Across 19 Phase 1, 2 and 3 Trials with More Than 28,000 Participants WHO Will Consider the SAGE Recommendation and Provide Final Guidance on the Use of QDENGA in Public Vaccination Programs in the Coming Months De...